Daniel P. Petrylak, MD, recently named Leader of Prostate Medical Oncology at Yale Cancer Center in New Haven, CT. Dr. Petrylak, an internationally known medical oncologist, to lead the genitourinary cancers medical oncology team at Smilow Cancer Hospital and as director of the prostate cancer research group and co-director of the Signal Transduction Research Program. Dr. Petrylak joins Yale from NewYork-Presbyterian Hospital/Columbia University Medical Center.

Dr. Petrylak graduated from Columbia College in New York and earned his medical degree from Case Western Reserve University of Medicine in Cleveland, Ohio. He served his internship and residency in internal medicine at Albert Einstein College of Medicine and went on to complete a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center, also both in New York. A diplomat of internal medicine and medical oncology, Dr. Petrylak has received several grants and funding support from the National Institutes of Health, private foundations such as CaP CURE and the pharmaceutical industry to study cancer treatments. Since 1995, Dr. Petrylak has been a chairman of the Advanced Bladder Subcommittee of the Southwest Oncology Group (SWOG), a network of institutions and investigators working to improve the survival of cancer patients through clinical research. Dr. Petrylak instructs medical students on the formal principles of cancer chemotherapy as part of the Abnormal Human Biology course at the College of Physicians and Surgeons. He has authored or co-authored numerous articles and abstracts appearing in such peer-reviewed journals as Cancer, Cancer Research, Clinical Cancer Research, Journal of the National Cancer Institute, Nature, Journal of Urology New England Journal of Medicine, and Journal of Clinical Oncology. In addition, Dr. Petrylak has presented his research at numerous medical conferences, had a plenary sessions at ASCO and the AUA this year. He has authored several book chapters, reviews and editorials about the treatment of cancers of the prostate, bladder and kidney. Dr. Petrylak is a member of several medical societies, including the American Association for Cancer Research, the American Society for Clinical Oncology, and the American Urological Association. He also served as a member of the Devices and Immunological Committee of the U.S. Food and Drug Administration (FDA).

Prostate cancer is a disease that is most successfully treated when it is detected early on.  As the research community explores various methods to detecting the disease, PCEC continues to encourage men to play an active role in their health by looking to those trusted sources of prostate cancer testing – the PSA and DRE.

Join Our Newsletter